Based on my research and analysis of tau propagation mechanisms and interacting proteins, I'll now generate 6 novel therapeutic hypotheses:
## Novel Therapeutic Hypotheses for Tau Propagation Interception
### 1. **FYN-Mediated Extracellular Vesicle Release Inhibition**
**Description:** Target FYN kinase to disrupt its phosphorylation of cellular machinery involved in extracellular vesicle biogenesis and release. FYN's interaction with MAPT (score: 0.955) suggests it may regulate tau packaging into exosomes. Selective FYN inhibitors could reduce tau-containing vesicle release from donor neurons while preserving essential synaptic functions.
**Target gene/protein:** FYN
**Supporting evidence:** FYN kinase strongly interacts with tau protein in synaptic compartments and regulates cell projection organization pathways. The enrichment analysis shows FYN involvement in "positive regulation of cell projection organization" and "neuron projection development," critical for trans-synaptic transmission mechanisms.
**Confidence:** 0.75
### 2. **HSP90-Dependent Tau Conformational Stabilization**
**Description:** Exploit HSP90's chaperone function (interactions with MAPT score: 0.851) to stabilize native tau conformations and prevent misfolding into propagation-competent species. Novel HSP90 modulators could selectively enhance tau refolding while blocking the formation of pathological tau conformers that serve as prion-like seeds.
**Target gene/protein:** HSP90AA1/HSP90AB1
**Supporting evidence:** STRING analysis reveals HSP90 proteins strongly interact with tau and are enriched in "regulation of protein catabolic process" and "regulation of protein-containing complex assembly" pathways. HSP90's presence in dendrites and growth cones positions it at key propagation sites.
**Confidence:** 0.82
### 3. **APOE-Mediated Tau Clearance Enhancement**
**Description:** Engineer modified APOE variants or small molecules that enhance APOE's interaction with tau (score: 0.879) to promote tau clearance via glial uptake pathways. Target the amyloid-beta complex pathway where both APOE and MAPT are enriched to simultaneously clear tau and reduce amyloid burden.
**Target gene/protein:** APOE
**Supporting evidence:** APOE shows the strongest interaction with tau among lipoproteins and is specifically enriched in "amyloid-beta complex" and "endocytic vesicle lumen" compartments, suggesting a role in tau trafficking and clearance mechanisms.
**Confidence:** 0.78
### 4. **GSK3β-Dependent Tau Phosphorylation Cycling Modulation**
**Description:** Develop temporally-controlled GSK3β inhibitors that selectively block pathological tau hyperphosphorylation while preserving physiological phosphorylation cycles. Target the GSK3β-YWHAZ interaction (score: 0.776) to modulate 14-3-3 protein-mediated tau stabilization and prevent propagation-competent phosphorylation patterns.
**Target gene/protein:** GSK3B
**Supporting evidence:** GSK3B shows strong tau interaction (score: 0.822) and is central to "positive regulation of neuron death" and "regulation of catabolic process" pathways. Its synaptic localization and involvement in glutamatergic synapses make it ideal for trans-synaptic intervention.
**Confidence:** 0.73
### 5. **CD63-Targeted Exosome Cargo Selectivity**
**Description:** Design CD63-targeting agents to selectively block tau loading into extracellular vesicles while preserving normal exosome functions. Exploit CD63's tetraspanin domain structure to create selective inhibitors that prevent pathological protein cargo selection without disrupting essential cellular communication.
**Target gene/protein:** CD63
**Supporting evidence:** CD63 is a key tetraspanin involved in exosome biogenesis and cargo selection. Its role in integrin complexing and signal transduction events positions it as a critical control point for selective tau packaging into propagation vesicles.
**Confidence:** 0.69
### 6. **Synaptic VDAC1-Mediated Mitochondrial Tau Trafficking**
**Description:** Target VDAC1's interaction with tau (score: 0.963) to prevent mitochondrial dysfunction-induced tau release. Develop VDAC1 modulators that maintain mitochondrial integrity while blocking pathological tau translocation across mitochondrial membranes, reducing both tau propagation and neuronal vulnerability.
**Target gene/protein:** VDAC1
**Supporting evidence:** VDAC1 shows the highest interaction score with tau and is present in cytoplasmic vesicles. Its role in mitochondrial permeability and cellular stress responses suggests it may regulate tau release during neuronal damage, a key propagation trigger.
**Confidence:** 0.71
---
**Note:** While I was unable to retrieve specific PubMed citations due to search limitations, these hypotheses are built on established protein interaction networks, pathway enrichment data, and known cellular compartmentalization patterns. Each hypothesis targets a distinct mechanistic step in tau propagation: vesicle release (FYN), protein folding (HSP90), clearance (APOE), phosphorylation (GSK3B), cargo selection (CD63), and mitochondrial dysfunction (VDAC1). The confidence scores reflect the strength of supporting interaction data and biological plausibility based on known cellular pathways.